CLINICAL_TRIALS ClinicalTrials.gov record update

Safety, Immunogenicity and Consistency of 3 Manufacturing Lots of DTaP-IPV Vaccine Versus Separate Injections of GSK Biologicals' DTaP + Aventis Pasteur's IPV Administered as Booster Doses to Healthy Children 4-6 Years, Each Co-administered With Merck's MMR Vaccine

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00148941
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:25.210756+00:00
Published At: 2020-02-05T00:00:00+00:00
Record Updated At: 2020-02-05
Results Posted At: 2020-02-05
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Tetanus", "Acellular Pertussis", "Diphtheria"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2020-02-05"
protocolSection.identificationModule.nctId: "NCT00148941"
protocolSection.identificationModule.officialTitle: "Safety, Immunogenicity and Consistency of 3 Manufacturing Lots of DTaP-IPV Vaccine Versus Separate Injections of GSK Biologicals\u0027 DTaP + Aventis Pasteur\u0027s IPV Administered as Booster Doses to Healthy Children 4-6 Years, Each Co-administered With Merck\u0027s MMR Vaccine"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2020-02-05"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.